Literature DB >> 12746229

Pharmacological characterisation of native somatostatin receptors in AtT-20 mouse tumour corticotrophs.

Davide Cervia1, Caroline Nunn, Dominique Fehlmann, Daniel Langenegger, Edi Schuepbach, Daniel Hoyer.   

Abstract

1. The mouse corticotroph tumour cell line AtT-20 is a useful model to investigate the physiological role of native somatostatin (SRIF, Somatotropin release inhibitory factor) receptor subtypes (sst(1) - sst(5)). The objective of this study was to characterise the pharmacological features and the functional effects of SRIF receptors expressed by AtT-20 cells using radioligand binding and cAMP accumulation. 2. [(125)I]LTT-SRIF-28, [(125)I]CGP 23996, [(125)I]Tyr(10)-cortistatin-14 and [(125)I]Tyr(3)-octreotide labelled SRIF receptor binding sites with high affinity and in a saturable manner (B(max)=315, 274, 239 and 206 fmol mg(-1), respectively). [(125)I]LTT-SRIF-28 labels significantly more sites than [(125)I]Tyr(10) -cortistatin-14 and [(125)I]Tyr(3) -octreotide as seen previously in cells expressing pure populations of sst(2) or sst(5) receptors. 3. SRIF analogues displaced the binding of the four radioligands. sst(2/5) receptor-selective ligands showed much higher affinity than sst(1/3/4) receptor-selective ligands. The binding profile of [(125)I]Tyr(3)-octreotide was different from that of [(125)I]LTT-SRIF-28, [(125)I]CGP 23996 and [(125)I]Tyr(10)-cortistatin-14. The sst(5/1) receptor-selective ligand L-817,818 identified two binding sites, one with subnanomolar affinity (sst(5) receptors) and one with micromolar affinity (sst(2) receptors); however, the proportions were different: 70 - 80% high affinity with [(125)I]LTT-SRIF-28, [(125)I]CGP 23996, [(125)I]Tyr(10)-cortistatin-14, but only 20% with [(125)I]Tyr(3)-octreotide. 4. SRIF analogues inhibited the forskolin-stimulated cAMP levels depending on concentration. sst(2/5) receptor-selective ligands were highly potent, whereas sst(1/3/4) receptor-selective ligands had no significant effects. The sst(2) receptor antagonist D-Tyr(8)-CYN 154806 competitively antagonised the effects of SRIF-14 and sst(2) receptor-preferring agonists, but not those of L-817,818. 5. The complex binding properties of SRIF receptor analogues indicate that sst(2) and sst(5) receptors are the predominant SRIF receptors expressed on AtT-20 cell membranes with no or only negligible presence of sst(1), sst(3) and sst(4) receptors. In the functional studies using cAMP accumulation, only sst(2) and sst(5) receptors appear to play a role. However, the "predominant" receptor appears to be the sst(2) receptor, although sst(5) receptors can also mediate the effect, when the ligand is not able to activate sst(2) receptors. This clearly adds flexibility to SRIF-mediated functional effects and suggests that the physiological role of SRIF and its analogues may be mediated preferentially via one subtype over another.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12746229      PMCID: PMC1573832          DOI: 10.1038/sj.bjp.0705235

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  44 in total

1.  Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity.

Authors:  M Rocheville; D C Lange; U Kumar; S C Patel; R C Patel; Y C Patel
Journal:  Science       Date:  2000-04-07       Impact factor: 47.728

2.  Small molecule somatostatin receptor subtype-2 antagonists.

Authors:  B A Hay; B M Cole; F M DiCapua; G W Kirk; M C Murray; R A Nardone; D J Pelletier; A P Ricketts; A S Robertson; T W Siegel
Journal:  Bioorg Med Chem Lett       Date:  2001-10-22       Impact factor: 2.823

3.  Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers.

Authors:  M Rocheville; D C Lange; U Kumar; R Sasi; R C Patel; Y C Patel
Journal:  J Biol Chem       Date:  2000-03-17       Impact factor: 5.157

4.  Characterisation of human recombinant somatostatin receptors. 1. Radioligand binding studies.

Authors:  S Siehler; K Seuwen; D Hoyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1999-11       Impact factor: 3.000

5.  Homo- and heterodimerization of somatostatin receptor subtypes. Inactivation of sst(3) receptor function by heterodimerization with sst(2A).

Authors:  M Pfeiffer; T Koch; H Schröder; M Klutzny; S Kirscht; H J Kreienkamp; V Höllt; S Schulz
Journal:  J Biol Chem       Date:  2000-12-27       Impact factor: 5.157

6.  Identification of potent non-peptide somatostatin antagonists with sst(3) selectivity.

Authors:  L Poitout; P Roubert; M O Contour-Galcéra; C Moinet; J Lannoy; J Pommier; P Plas; D Bigg; C Thurieau
Journal:  J Med Chem       Date:  2001-08-30       Impact factor: 7.446

7.  Cloning, expression and pharmacological characterisation of the mouse somatostatin sst(5) receptor.

Authors:  D Feuerbach; D Fehlmann; C Nunn; S Siehler; D Langenegger; R Bouhelal; K Seuwen; D Hoyer
Journal:  Neuropharmacology       Date:  2000-06-08       Impact factor: 5.250

8.  Pharmacological characterisation of the goldfish somatostatin sst5 receptor.

Authors:  Caroline Nunn; Dominik Feuerbach; Xinwei Lin; Richard Peter; Daniel Hoyer
Journal:  Eur J Pharmacol       Date:  2002-02-02       Impact factor: 4.432

Review 9.  Drug design at peptide receptors: somatostatin receptor ligands.

Authors:  Jason P Hannon; Caroline Nunn; Barbara Stolz; Christians Bruns; Gisbert Weckbecker; Ian Lewis; Thomas Troxler; Konstanze Hurth; Daniel Hoyer
Journal:  J Mol Neurosci       Date:  2002 Feb-Apr       Impact factor: 3.444

10.  Somatostatin sst2 receptor knock-out mice: localisation of sst1-5 receptor mRNA and binding in mouse brain by semi-quantitative RT-PCR, in situ hybridisation histochemistry and receptor autoradiography.

Authors:  J P Hannon; C Petrucci; D Fehlmann; C Viollet; J Epelbaum; D Hoyer
Journal:  Neuropharmacology       Date:  2002-03       Impact factor: 5.250

View more
  9 in total

1.  Native somatostatin sst2 and sst5 receptors functionally coupled to Gi/o-protein, but not to the serum response element in AtT-20 mouse tumour corticotrophs.

Authors:  Davide Cervia; Dominique Fehlmann; Daniel Hoyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-05-15       Impact factor: 3.000

2.  Somatostatin coupling to adenylyl cyclase activity in the mouse retina.

Authors:  Barbara Pavan; Sara Fiorini; Massimo Dal Monte; Laura Lunghi; Carla Biondi; Paola Bagnoli; Davide Cervia
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-08-12       Impact factor: 3.000

3.  Identification of Phosphorylation Sites Regulating sst3 Somatostatin Receptor Trafficking.

Authors:  Andreas Lehmann; Andrea Kliewer; Thomas Günther; Falko Nagel; Stefan Schulz
Journal:  Mol Endocrinol       Date:  2016-04-21

Review 4.  The role of somatostatin analogs in Cushing's disease.

Authors:  Joost van der Hoek; Steven W J Lamberts; Leo J Hofland
Journal:  Pituitary       Date:  2004       Impact factor: 4.107

5.  Characterization of agonist-dependent somatostatin receptor subtype 2 trafficking in neuroendocrine cells.

Authors:  Walaa Alshafie; Yingzhou Edward Pan; Hans-Jürgen Kreienkamp; Thomas Stroh
Journal:  Endocrine       Date:  2020-05-07       Impact factor: 3.633

Review 6.  Somatostatin and dopamine receptors as targets for medical treatment of Cushing's Syndrome.

Authors:  C de Bruin; R A Feelders; S W J Lamberts; L J Hofland
Journal:  Rev Endocr Metab Disord       Date:  2008-07-19       Impact factor: 6.514

7.  Pathophysiology of GPCR Homo- and Heterodimerization: Special Emphasis on Somatostatin Receptors.

Authors:  Rishi K Somvanshi; Ujendra Kumar
Journal:  Pharmaceuticals (Basel)       Date:  2012-04-27

Review 8.  Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 1--molecular pathways.

Authors:  Mehtap Cakir; Dorota Dworakowska; Ashley Grossman
Journal:  J Cell Mol Med       Date:  2010-11       Impact factor: 5.310

9.  The Neuropeptide Systems and their Potential Role in the Treatment of Mammalian Retinal Ischemia: A Developing Story.

Authors:  D Cervia; G Casini
Journal:  Curr Neuropharmacol       Date:  2013-01       Impact factor: 7.363

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.